|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue, West Montreal, Quebec H3A 1A1, Canada
Lipid Research Centre, Centre Hospitalier Universitaire de Québec Research Centre and Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Canada
Laboratoire de Physiologie et de la Nutrition, Universite Paris Sud, Orsay, France
1 To whom correspondence should be addressed. e-mail: katherine.cianflone{at}mcgill.ca
Postprandial plasma triglyceride (ppTG) and NEFA clearance were stratified by plasma acylation-stimulating protein (ASP) and gender to determine the contribution of fasting ASP in a normal population (70 men; 71 women). In the highest ASP tertile only, ASP decreased over 8 h (90 ± 9.7 nM to 70 ± 5.9 nM, P < 0.05 males; 61.9 ± 4.0 nM to 45.6 ± 6.2 nM, P < 0.01 females). Fasting ASP correlated positively with ppTG response. ppTG (P < 0.0001, 2-way ANOVA, both genders) and NEFA levels progressively increased from lowest to highest ASP tertile, with the greatest differences in males. By stepwise multiple regression, the best prediction of ppTG was: (fasting ASP + apolipoprotein B + insulin + TG; r = 0.806) for men and (fasting ASP + total cholesterol; r = 0.574) for women. Leptin, body mass index, and other fasting variables did not improve the prediction. Thus, in men and women, ASP significantly predicted ppTG and NEFA clearance and, based on lower ASP, women may be more ASP sensitive than men.
Plasma ASP may be useful as a fasting variable that will provide additional information regarding ppTG and NEFA clearance.
Abbreviations: ASP, acylation-stimulating protein; BMI, body mass index; HOMA, homeostatic model of insulin resistance; iAUC, incremental area under the curve; RM-ANOVA, repeated measures analyses of variance; TG, triglyceride
Supplementary key words C3adesArg fatty acid insulin leptin
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Paglialunga, A. Fisette, Y. Yan, Y. Deshaies, J.-F. Brouillette, M. Pekna, and K. Cianflone Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E521 - E529. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cui, S. Paglialunga, D. Kalant, H. Lu, C. Roy, M. Laplante, Y. Deshaies, and K. Cianflone Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1482 - E1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Marcil, H. Vu, W. Cui, Z. Dastani, J. C. Engert, D. Gaudet, M. Castro-Cabezas, A. D. Sniderman, J. Genest Jr, and K. Cianflone Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1619 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maslowska, H. Legakis, F. Assadi, and K. Cianflone Targeting the signaling pathway of acylation stimulating protein J. Lipid Res., March 1, 2006; 47(3): 643 - 652. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |